title: Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.
abstract: BACKGROUND
  Adjuvant treatment for pancreatic adenocarcinoma has been shown to improve survival. An increasingly recognized 'subtype' of pancreatic adenocarcinoma is invasive intraductal papillary mucinous neoplasm (IPMN). It is unclear whether adjuvant treatment for invasive IPMN improves survival. This study aimed to determine the impact of adjuvant treatment in invasive IPMN.
  
  
  METHODS
  We conducted a retrospective analysis of merged clinical databases including 412 patients undergoing resection for IPMN at two academic institutions between 1989 and 2006.
  
  
  RESULTS
  Of 412 patients with IPMN who underwent pancreatectomy, 98 had invasive carcinoma. Median survival in invasive IPMN was 32 months. Adjuvant treatment did not affect median survival in node-positive or node-negative invasive IPMN. Biopsy-proven recurrence of invasive IPMN occurred in 45 patients (46%). The median disease-free interval from resection to recurrence was 27 months. Treatment of recurrences with chemotherapy or radiation therapy was not associated with a difference in survival; however, a subgroup of patients with recurrence in the remnant pancreas who underwent re-resection appeared to have more favourable outcomes.
  
  
  CONCLUSIONS
  An invasive component measuring >2 cm and lymph node involvement are associated with poorer prognosis. Adjuvant therapy in invasive IPMN appears to confer no survival benefit. In selected patients with recurrence of invasive IPMN in the remnant pancreas, re-resection should be considered.
authors.affiliation: Department of Surgery, Indiana University, Indianapolis, IN, USA.
authors.forename: Olivier
authors.initials: O
authors.lastname: Turrini
authors.forename: Joshua A
authors.initials: JA
authors.lastname: Waters
authors.forename: Thomas
authors.initials: T
authors.lastname: Schnelldorfer
authors.forename: Keith D
authors.initials: KD
authors.lastname: Lillemoe
authors.forename: Constantin T
authors.initials: CT
authors.lastname: Yiannoutsos
authors.forename: Michael B
authors.initials: MB
authors.lastname: Farnell
authors.forename: Michael G
authors.initials: MG
authors.lastname: Sarr
authors.forename: C Max
authors.initials: CM
authors.lastname: Schmidt
mesh_terms: D000368:Aged; D001706:Biopsy; D021441:Carcinoma, Pancreatic Ductal / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007196:Indiana; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008910:Minnesota; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000601:surgery; D009367:Neoplasm Staging; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D010180:Pancreatectomy / Q000401:mortality; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D012086:Reoperation; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
references.citation: J Am Coll Surg. 2007 Mar;204(3):347-55
references.pmid: 17324767
references.citation: Surgery. 2006 Sep;140(3):448-53
references.pmid: 16934608
references.citation: Surgery. 2008 Oct;144(4):677-84; discussion 684-5
references.pmid: 18847654
references.citation: Eur J Surg Oncol. 2009 Jun;35(6):600-4
references.pmid: 19131205
references.citation: Adv Surg. 2008;42:87-108
references.pmid: 18953811
references.citation: Ann Surg Oncol. 2009 Apr;16(4):836-47
references.pmid: 19194760
references.citation: Surgery. 2006 May;139(5):591-8
references.pmid: 16701090
references.citation: Am J Surg. 2005 May;189(5):632-6; discussion 637
references.pmid: 15862510
references.citation: J Am Coll Surg. 2008 Oct;207(4):510-9
references.pmid: 18926452
references.citation: Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4
references.pmid: 17893501
references.citation: J Gastrointest Surg. 2007 Nov;11(11):1549-55
references.pmid: 17786531
references.citation: Am J Surg Pathol. 2008 Feb;32(2):243-55
references.pmid: 18223327
references.citation: Cancer. 2002 Jan 1;94(1):62-77
references.pmid: 11815961
references.citation: Br J Cancer. 2009 Jan 27;100(2):246-50
references.pmid: 19127260
references.citation: Ann Surg. 2004 Mar;239(3):400-8
references.pmid: 15075659
references.citation: Ann Surg. 2008 Jul;248(1):97-103
references.pmid: 18580212
references.citation: Surg Endosc. 2006 Apr;20 Suppl 2:S446-9
references.pmid: 16557419
references.citation: JAMA. 2007 Jan 17;297(3):267-77
references.pmid: 17227978
references.citation: Ann Surg. 2010 Mar;251(3):470-6
references.pmid: 20142731